Clinical Study

Day 100 Peripheral Blood Absolute Lymphocyte/Monocyte Ratio and Survival in Classical Hodgkin's Lymphoma Postautologous Peripheral Blood Hematopoietic Stem Cell Transplantation

Table 1

Baseline patient characteristics.

Characteristics (%)MedianRange

At diagnosis
Age, years131 (100%)32(18–68)
Gender
 Male67 (51%)
 Female64 (49%)
Albumin (g/dL)127 (97%)4(2.0–4.6)
ALC × 109/L131 (100%)1.3(0.2–2.9)
Hemoglobin (g/dL)131 (100%)12.2(7.7–16.2)
Mediastinal disease
 ≥10 cm21 (16%)
 <10 cm110 (84%)
Stage
 I6 (4%)
 II56 (43%)
 III35 (27%)
 IV34 (26%)
Stage
 Limited61 (47%)
 Advanced69 (53%)
WBC × 109/L131 (100%)8.3(1.4–22.2)
IPS risk factors
Age, years
 ≤45109 (83%)
 >4522 (17%)
Albumin (g/dL) ( = 127)
 ≥480 (63%)
 <447 (37%)
ALC × 109/L
 ≥0.6106 (81%)
 <0.625 (19%)
Hemoglobin (g/dL)
 >10.5102 (78%)
 ≤10.529 (22%)
Male67 (51%)
Stage 434 (26%)
WBC × 109/L
 >1520 (15%)
 ≤15111 (85%)
IPS score
 030 (23%)
 141 (31%)
 227 (21%)
 313 (10%)
 410 (8%)
 57 (5%)
 63 (2%)
IPS index
 ≥333 (25%)
 <398 (75%)
At transplant
Infused CD34+ stem cell × 106/kg131 (100%)5.1(2.1–15.8)
Pretransplant response
 CR30 (23%)
 PR101 (77%)
At Day 15 post-APBHSCT
ALC × 109/L131 (100%)0.67(0.1–3.67)
ALC × 109/L
 ≥0.590 (69%)
 <0.541 (31%)
At day 100 post-APBHSCT
Age, years131 (100%)35(18–69)
Hemoglobin (g/dL)131 (100%)11.9(7.3–16.7)
WBC × 109/L131 (100%)4.4(1.5–14.3)
ANC × 109/L131 (100%)2.54(1.2–10.01)
ALC × 109/L131 (100%)1.09(0.15–4.61)
AMC × 109/L131 (100%)0.46(0.15–4.02)
ALC/AMC131 (100%)2.5(0.18–11.07)
Plts × 109/L131 (100%)164(55.2–373)

Abbreviations: ALC: absolute lymphocyte count; ANC: absolute neutrophil count; AMC: absolute monocyte count; CR: complete remission; IPS: International Prognostic Score; PR: partial response; Plts: platelets; and WBC: white blood cell count.